CDNF and MANF: Complete Research Profile — The ER-Resident Neurotrophic Factor Family in Parkinson's Disease, Neurodegeneration, and Cytoprotection Research (2026)

# CDNF and MANF: Complete Research Profile

The ER-Resident Neurotrophic Factor Family in Parkinson's Disease, Neurodegeneration, and Cytoprotection Research (2026)

Cerebral Dopamine Neurotrophic Factor (CDNF) and Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) constitute an evolutionarily conserved family of unconventional neurotrophic proteins that operate through a mechanism fundamentally distinct from classical neurotrophins such as NGF or BDNF. Rather than acting primarily through extracellular receptor tyrosine kinase signaling, CDNF and MANF exert their cytoprotective effects largely from within the endoplasmic reticulum (ER) lumen, where they modulate the unfolded protein response (UPR) and suppress ER stress–induced apoptosis. This intracellular-first mechanism makes them uniquely relevant to diseases characterized by protein misfolding and chronic ER stress — most prominently Parkinson's disease (PD), but also type 1 and type 2 diabetes, retinal degeneration, and cardiac ischemia.

For research laboratories, CDNF and MANF represent both powerful model tools for dissecting ER proteostasis biology and compelling therapeutic candidates in the preclinical and early clinical pipeline. This profile covers their discovery, structural biology, molecular mechanism, tissue distribution, model organism data, and current translational trajectory — with all content framed for Research Use Only (RUO) purposes.

---

Discovery and Naming History

MANF was first described in 2003 by Petrova and colleagues, who identified it as a secreted survival factor released from rat type-1 astrocyte-conditioned medium that promoted the survival of dopaminergic neurons in vitro. The name reflects its mesencephalic astrocyte origin and neurotrophic activity. The human gene MANF encodes a 179-amino-acid precursor with an N-terminal signal peptide and a C-terminal KDEL ER retention sequence.

CDNF was discovered in 2007 by Lindholm and colleagues (PMID: 36794783, 34907395, 34180421) at the University of Helsinki through a bioinformatics screen for MANF homologs ([Lindholm et al., 2007, Science]()). The 187-amino-acid protein demonstrated potent protection and rescue of nigral dopaminergic neurons in a 6-OHDA rat model of Parkinson's disease — outperforming GDNF in some parameters of striatal dopamine fiber density recovery. The discovery generated significant excitement because the GDNF family, previously considered the gold standard for dopaminergic neurotrophic support, had encountered setbacks in clinical trials, and CDNF offered a structurally and mechanistically novel alternative.

Together, CDNF and MANF are now recognized as the founding members of the CDNF/MANF family, distinct from all other known neurotrophic factor families.

---

Protein Structure: The Bifunctional Two-Domain Architecture

CDNF and MANF share a strikingly similar two-domain architecture that encodes their bifunctional behavior — acting both extracellularly as secreted growth factors and intracellularly as ER chaperone-modulators.

N-Terminal Saposin-Like Domain

The N-terminal domain (~100 residues) adopts a saposin-fold, a five-helix bundle conserved in lipid-transfer and membrane-interaction proteins. In classical saposins, this fold mediates lipid bilayer binding and lysosomal sphingolipid metabolism. In CDNF and MANF, the saposin-like domain is thought to contribute to the extracellular neurotrophic activity, potentially through interaction with membrane lipids or extracellular matrix components. Crystal structures of both proteins confirm this helix-bundle topology ([Parkash et al., 2009, PLoS ONE]()).

C-Terminal SAP Domain and CXXC Motif

The C-terminal domain (~80 residues) adopts a SAP (SAF-A/B, Acinus, PIAS) domain fold and contains two functionally critical features:

1. CXXC motif — a disulfide-forming cysteine pair (CRAC in CDNF; CKGC in MANF) that participates in thiol/disulfide redox chemistry. This motif is structurally analogous to the active site of thioredoxin-like oxidoreductases, suggesting CDNF and MANF may function as atypical ER oxidoreductases or redox sensors.

2. KDEL-type ER retention sequence — KTEL in CDNF; RTDL in MANF. These C-terminal tetrapeptides interact with KDEL receptors on the Golgi, retrieval proteins, and ensure that the bulk of the cellular pool remains ER-localized. Critically, disruption of the ER retention sequence markedly increases secretion, revealing that regulated release is a key control point for CDNF/MANF biology.

The two-domain structure explains the "bifunctional" designation: the N-terminal saposin fold provides extracellular trophic capacity while the C-terminal domain anchors intracellular ER function ([Parkash et al., 2009]()).

Secretion Regulation

Under basal conditions, ER-resident CDNF and MANF are continuously retrieved from the Golgi via KDEL receptor–mediated retrograde transport. Under ER stress, this retrieval becomes saturated, and a fraction of the protein escapes into the secretory pathway, enabling autocrine/paracrine signaling at cell surface receptors. Experimental disruption of helix-7 in the CDNF C-terminal domain markedly amplifies secretion, providing a research tool to decouple intracellular from extracellular functions (Bai et al., 2015, BBRC).

---

Mechanism of Action: ER Stress Modulation and UPR Interplay

The central mechanistic insight for the CDNF/MANF field is that these proteins act as endogenous modulators of the unfolded protein response (UPR), shifting the balance from the pro-apoptotic arm toward adaptive, pro-survival signaling.

The UPR Context

ER stress occurs when misfolded protein load exceeds the ER's folding capacity. The master chaperone GRP78 (BiP) acts as a sentinel: under basal conditions, GRP78 binds and inactivates three ER stress sensors — IRE1α, PERK, and ATF6. When misfolded proteins accumulate, GRP78 dissociates from these sensors, triggering the UPR. The UPR has two competing outcomes:

• •Adaptive UPR: PERK-eIF2α-ATF4 and IRE1α-XBP1s branches reduce translation load and upregulate chaperone expression
• •Terminal UPR: Sustained stress activates CHOP (DDIT3) and caspase-12/4, driving apoptosis

CDNF Interaction with GRP78

CDNF physically binds GRP78 at its nucleotide-binding domain, as confirmed by structural studies (Lindström et al., 2024, PMC). This interaction appears to stabilize GRP78's ATPase cycle, enhancing its chaperoning capacity. Mutating key residues in the CDNF-GRP78 interface abolishes neuroprotective activity in cell culture models, establishing this interaction as mechanistically load-bearing.

IRE1α and PERK Dependence

RNA interference studies demonstrate that CDNF's protection from ER stress-induced apoptosis requires intact IRE1α and PERK signaling: knockdown of either sensor significantly blunts CDNF's protective effect (Voutilainen et al., 2022, PMC). This indicates CDNF is not simply a passive chaperone but an active modulator that routes UPR signaling toward adaptive rather than terminal outcomes.

A 2024 preprint extended this to human iPSC-derived dopamine neurons, showing CDNF directly binds PERK and IRE1α sensor domains and biases their activation profiles toward pro-survival gene expression programs, including upregulation of XBP1s and ATF4 target genes while suppressing CHOP.

MANF's Overlapping but Distinct Mechanism

MANF shares the GRP78-interaction and UPR-modulatory capacity but exhibits tissue-specific regulatory differences from CDNF. A landmark study by Danilova et al. (2022, PMC) demonstrated that combined loss of both CDNF and MANF in muscle led to exacerbated UPR activation, whereas combined loss in the brain did not — revealing non-redundant, tissue-compartmentalized functions. MANF additionally interacts with sulfatide lipids via its saposin-like domain, a property that may mediate its effects in non-neuronal tissues such as the pancreatic islet.

---

CDNF in Dopaminergic Neuron Biology

6-OHDA and MPTP Rodent Models

The defining preclinical evidence for CDNF in PD research derives from neurotoxin models:

• •6-OHDA model (rat): Unilateral injection of 6-hydroxydopamine into the medial forebrain bundle or striatum destroys nigrostriatal dopamine neurons. Intrastriatal injection of CDNF 2 weeks post-lesion rescued ~75% of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra pars compacta (SNpc) and restored striatal dopamine fiber density to near-control levels ([Lindholm et al., 2007, Science]()). Behavioral measures — apomorphine-induced rotations — normalized in CDNF-treated animals.

• •MPTP model (mouse): Systemic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) recapitulates many features of PD. AAV-mediated CDNF delivery to the striatum prior to MPTP administration preserved ~80% of TH+ SNpc neurons and reduced striatal MPTP-induced ER stress markers including GRP78 upregulation and CHOP expression (Bjoerklund et al., 2024, Scientific Reports).

These studies establish CDNF as both neuroprotective (preventing loss when administered before or shortly after insult) and neurorestorative (partial recovery when administered weeks post-lesion).

Alpha-Synuclein Models

More disease-relevant α-synuclein overexpression models show that CDNF delivery attenuates α-synuclein aggregation, with direct CDNF-α-synuclein interaction reducing its auto-association and aggregation in vivo (PMID: 33940158) burden and preserves dopamine neuron survival, likely because α-synuclein pathology is tightly linked to ER stress and disrupted ER-Golgi trafficking. The convergence of ER stress as a shared mechanism positions CDNF as uniquely suited among neurotrophic factors for synucleinopathy contexts.

---

MANF's Broader Cytoprotective Portfolio

While CDNF research has focused primarily on the nigrostriatal system, MANF exhibits a wider cytoprotective portfolio reflecting its higher endogenous expression in metabolically demanding tissues.

Pancreatic Beta Cells and Diabetes Research

Pancreatic β cells are among the most ER-stressed cells in the body, synthesizing vast quantities of proinsulin that must be correctly folded and processed within the ER. MANF is highly expressed in β cells and is further induced by ER stress. Genetic deletion of MANF in mice leads to progressive diabetes due to accelerated β cell apoptosis and reduced proliferation — a phenotype rescued by exogenous MANF administration (Lindahl et al., 2014, Nature Cell Biology). Subsequent studies demonstrated MANF delivery to NOD mouse pancreatic islets protected against autoimmune β cell destruction, implicating MANF as both a pro-survival factor and an immunomodulator in the islet microenvironment (Pätäri-Sampo et al., PMC).

Retinal Photoreceptor Protection

MANF is expressed in retinal ganglion cells and photoreceptors. In light-induced retinal degeneration models and rd10 mice (retinitis pigmentosa model), intraocular MANF administration preserves photoreceptor layer thickness and electroretinogram responses. ER stress is a shared feature of multiple inherited retinal dystrophies, making MANF a candidate research reagent for investigating retinal ER stress biology.

Cardiac Ischemia-Reperfusion

Myocardial ischemia triggers ER stress in cardiomyocytes. Both CDNF and MANF are upregulated in ischemic myocardium, and their exogenous administration in rodent ischemia-reperfusion models reduces infarct size and preserves cardiac function, apparently by suppressing CHOP-mediated cardiomyocyte apoptosis. This suggests the CDNF/MANF family acts as a broad cytoprotective system engaged wherever ER stress threatens cell viability.

---

Evolutionary Conservation: Model Organism Insights

The CDNF/MANF family is ancient and highly conserved, with a single ancestral gene in invertebrates that gave rise to both CDNF and MANF through vertebrate-lineage duplication. This evolutionary depth provides powerful genetic model systems.

Drosophila melanogaster

The single Drosophila ortholog DmManf (also called CG4521) is essential for larval development — null mutants die as first-instar larvae. Importantly, mammalian MANF (but not CDNF) can rescue DmManf null lethality, confirming functional orthology. DmManf is upregulated by tunicamycin-induced ER stress and genetically interacts with Drosophila BiP (Hsc70-3), IRE1 (Ire1), and PERK (PEK) homologs (Palgi et al., 2009, PNAS). Adult flies with conditional DmManf knockdown show progressive dopaminergic neuron loss, validating the Parkinson's relevance of this pathway across phyla.

Caenorhabditis elegans

The C. elegans ortholog manf-1 is expressed in dopaminergic neurons and body wall muscles. manf-1 loss-of-function mutants exhibit accelerated age-dependent dopaminergic neuron degeneration and impaired UPR activation in response to tunicamycin and Pseudomonas aeruginosa infection (Richman et al., 2018, Frontiers in Neuroscience). These findings establish MANF/CDNF as a conserved node linking proteostasis stress to dopaminergic neuron health across 600 million years of evolution.

Zebrafish

In zebrafish (Danio rerio), both manf and cdnf are expressed in the developing brain with highest levels in the diencephalon. Morpholino-mediated knockdown of zebrafish manf produces ER stress and dopaminergic neuron loss in the posterior tuberculum — phenotypes reversed by ER stress-relieving compounds, further validating the ER stress–dopaminergic neuron axis.

---

Research Applications and Laboratory Tools

Recombinant Protein Production

Both CDNF and MANF are available as recombinant proteins expressed in E. coli or insect cell systems. Refolding from inclusion bodies is feasible but requires attention to correct disulfide formation in the CXXC motif and overall N-/C-domain folding. Mammalian expression systems (HEK293, CHO) yield correctly folded, glycosylated protein but at lower titers. Researchers should validate recombinant protein bioactivity using a TH-positive neuron survival assay in primary ventral mesencephalic cultures treated with 6-OHDA or thapsigargin.

Gene Delivery Approaches

• •AAV vectors: AAV2 and AAV9 have been used for intrastriatal CDNF delivery in rodent PD models. AAV serotype selection affects retrograde transduction efficiency to SNpc neurons; AAV2 has high striatal tropism while AAV9 crosses the blood-brain barrier with systemic delivery.
• •Lentiviral vectors: Used in vitro and in ex vivo slices for CDNF/MANF overexpression studies. Useful for establishing stable overexpression in dopaminergic cell lines (SH-SY5Y, MN9D).
• •mRNA delivery: Lipid nanoparticle-formulated CDNF mRNA is an emerging approach that avoids insertional mutagenesis concerns and allows transient, dose-controllable expression.

Cellular Models

• •SH-SY5Y neuroblastoma (differentiated with retinoic acid + BDNF to dopaminergic phenotype): Standard model for CDNF neuroprotection assays using rotenone, 6-OHDA, or thapsigargin insults
• •Primary ventral mesencephalic cultures: Higher physiological relevance; contain TH+ neurons that can be quantified by immunofluorescence
• •Human iPSC-derived dopamine neurons: Most translatable model; CDNF protects these neurons from α-synuclein preformed fibril (PFF) insults and mitochondrial complex I inhibition
• •MIN6 and INS-1 β-cell lines: Standard models for MANF beta-cell research; ER stress induced by thapsigargin, tunicamycin, or cytokine cocktail (IL-1β + IFN-γ + TNF-α)

Biochemical and Imaging Assays

• •Co-immunoprecipitation (Co-IP): CDNF-GRP78 interaction is detectable by Co-IP from lysates of ER-stressed cells; validated with GST-pulldown using recombinant proteins
• •Proximity ligation assay (PLA): Enables visualization of endogenous CDNF-GRP78 proximity in situ
• •ER stress reporter systems: XBP1-luciferase or CHOP-GFP reporters quantify UPR branch activity in response to CDNF/MANF treatment
• •UPR Western blot panel: Key readouts include p-PERK/PERK, p-eIF2α/eIF2α, XBP1s, ATF4, CHOP, GRP78, and cleaved caspase-3/7

Commercially Available Reagents

Recombinant human CDNF and MANF proteins, neutralizing antibodies, ELISA kits for plasma/CSF measurement, and shRNA/siRNA constructs targeting both genes are commercially available from multiple suppliers. Researchers should verify lot-to-lot consistency in neurotrophic bioactivity assays given sensitivity of the proteins to freeze-thaw degradation and incorrect disulfide bonding.

---

Tissue Expression Profile

Understanding where CDNF and MANF are expressed guides experimental design:

MANF's exceptionally high expression in the liver and pancreatic β cells — tissues with extreme ER folding demands — reflects its role as a systemic ER homeostasis regulator. CDNF's relatively higher brain expression compared to MANF is consistent with its more CNS-focused activity profile.

---

Comparison with Classical Neurotrophins and GDNF Family

Placing CDNF and MANF in the broader neurotrophic factor landscape clarifies their research utility:

This comparison positions CDNF and MANF as occupying a mechanistically unique niche: they are the only neurotrophic factors that directly engage the UPR machinery, making them irreplaceable research tools for studying ER proteostasis in neurodegeneration.

---

Clinical Translational Trajectory

Note: All clinical information is presented for research context only. CDNF is an investigational compound; no regulatory approval exists for therapeutic use.

TreatER Phase 1/2 Trial

The TreatER study (NCT03295786) conducted by Herantis Pharma enrolled 17 subjects with moderately advanced Parkinson's disease and administered intraputamenal CDNF or placebo via a surgically implanted bilateral drug delivery system (DDS) for six monthly infusions. Results published in Movement Disorders (2023) demonstrated safety and tolerability of the DDS approach, with no serious adverse events attributable to CDNF infusions (Huttunen et al., 2023, Movement Disorders). Exploratory efficacy signals suggested potential benefits in motor assessments in a subset of subjects, though the trial was not powered for efficacy.

Herantis subsequently announced discontinuation of the intracranial infusion approach due to the surgical burden limiting patient eligibility and commercial viability — a strategic pivot toward non-invasive delivery.

HER-096: A Brain-Penetrating CDNF Mimetic

HER-096 is a small-molecule CDNF-derived peptidomimetic engineered for blood-brain barrier penetration and subcutaneous administration. Phase 1a results in healthy volunteers confirmed BBB penetration (CSF concentrations exceeding the preclinical target threshold) with an acceptable safety profile. A Phase 1b trial in PD subjects has received regulatory approval in Finland (Herantis Pharma, 2025). HER-096 maintains the GRP78-interaction and UPR-modulatory properties of full-length CDNF while achieving peripheral-to-CNS bioavailability — a significant advantage for chronic, non-surgical drug delivery.

Non-Invasive Peripheral CDNF Fragment Delivery

A 2025 bioRxiv preprint described a peripherally delivered CDNF fragment formulation that protects nigral neurons in both 6-OHDA rat and ALS mouse models, suggesting the ER stress–protective mechanism may extend to multiple neurodegenerative contexts (preprint, bioRxiv 2025).

---

Research Design Considerations

Choosing Between CDNF and MANF

• •Use CDNF when the primary research question involves dopaminergic neuron protection, the nigrostriatal system, or comparison with GDNF-family members
• •Use MANF when studying β-cell ER stress, metabolic disease models, retinal degeneration, or tissue contexts where MANF has higher endogenous expression
• •Use both for studies examining functional redundancy, UPR branch specificity, or tissue-specific phenotyping in knockout models

Dose and Route Considerations in Preclinical Models

Intrastriatal injection is the most validated route for CNS neurotrophic studies. Volumes of 2–4 µL per hemisphere with concentrations of 1–10 µg/µL are used in rat models. For in vitro work, concentrations of 1–100 ng/mL are typical in primary neuron and cell line models. Recombinant protein should be freshly reconstituted in BSA-containing carrier buffer to minimize adsorption losses.

Biomarker Readouts

For dopaminergic studies, the standard endpoint panel includes:

• •TH immunohistochemistry (SNpc cell body count + striatal fiber density)
• •Dopamine and metabolite HPLC from striatal tissue
• •Apomorphine-induced rotation behavior
• •Open-field locomotor activity

For ER stress mechanistic studies:

• •Western blot: GRP78, CHOP, p-PERK, p-eIF2α, XBP1s, ATF6 cleavage
• •RT-qPCR: HSPA5 (GRP78), DDIT3 (CHOP), XBP1s, ATF4, MANF, CDNF (often auto-induced by ER stress)
• •TUNEL or annexin V/PI flow cytometry for apoptosis quantification

---

Key Research Limitations and Open Questions

1. Extracellular receptor identity: Despite over 15 years of research, the cell-surface receptor(s) mediating the extracellular trophic effects of secreted CDNF and MANF remain uncharacterized. Identifying these receptors would clarify signaling cascades and enable structure-activity relationship studies for receptor-targeted peptidomimetics.

2. Structural mechanism of UPR modulation: While GRP78, PERK, and IRE1α interactions are established, the precise structural mechanism by which CDNF biases the UPR toward adaptive vs. terminal outcomes at the molecular level requires cryo-EM or X-ray crystallography of ternary complexes.

3. Endogenous regulation of secretion: What signals control the ER-retention/secretion balance in vivo during aging, neurodegeneration, or metabolic stress? Characterizing the endogenous secretory trigger could reveal novel regulatory intervention points.

4. Systemic versus CNS-specific delivery effects: For MANF, where endogenous expression is high in liver and pancreas, systemic delivery studies must distinguish CNS from peripheral pharmacology.

5. Long-term gene therapy safety: AAV-mediated CDNF overexpression studies extending beyond 12 months in NHP models are limited, leaving questions about trophic factor-induced toxicity at supraphysiological levels unresolved.

---

Summary: Why CDNF and MANF Matter for Research

CDNF and MANF occupy a mechanistically distinct position in the neurotrophic factor landscape. Their ER-resident, UPR-modulatory mechanism means they engage disease-relevant pathobiology — protein misfolding, ER stress, the adaptive-to-terminal UPR transition — at a point upstream of the neuronal death cascade that classical Trk or RET receptor-engaging growth factors do not reach. This makes them indispensable tools for:

• •Dissecting ER proteostasis in dopaminergic, β-cell, and cardiac contexts
• •Benchmarking neuroprotective interventions in 6-OHDA, MPTP, and α-synuclein models alongside GDNF-family members
• •Validating ER stress–specific therapeutic mechanisms in genetic and pharmacological UPR modulator studies
• •Studying evolutionary conservation of proteostasis–dopaminergic neuron coupling across invertebrate and vertebrate models

With HER-096 entering Phase 1b and the CDNF/MANF family's biology increasingly tractable at the structural level, this research area is poised to yield both mechanistic insights and translational outputs over the next 5–10 years.

---

All content on this page is intended for Research Use Only (RUO). CDNF and MANF are investigational compounds with no approved therapeutic indications. This article does not constitute medical advice, and the compounds described here are not approved for use in humans or animals outside of authorized research settings.

---

References and Further Reading

3. Palgi M et al. (2009). Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. PNAS, 106(7), 2429–2434. PubMed

4. Lindahl M et al. (2014). MANF is indispensable for the proliferation and survival of pancreatic β cells. Nature Cell Biology, 16(12), 1162–1172. PubMed

5. Voutilainen MH et al. (2022). CDNF Interacts with ER Chaperones and Requires UPR Sensors to Promote Neuronal Survival. eNeuro, 9(5). PMC

6. Danilova T et al. (2022). CDNF and MANF regulate ER stress in a tissue-specific manner. Cell Death & Disease, 13(2), 1–16. PMC

7. Huttunen HJ et al. (2023). Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: Phase 1 Trial. Movement Disorders, 38(8), 1461–1474. DOI

8. Richman C et al. (2018). C. elegans MANF Homolog Is Necessary for the Protection of Dopaminergic Neurons and ER Unfolded Protein Response. Frontiers in Neuroscience. PMC

9. Lindström R et al. (2024). Structural basis of CDNF interaction with the UPR regulator GRP78. PMC. PMC

(PMID: 42425390)

(PMID: 42425390)